Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priscilla Hollander

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The American Journal of Medicine|February 14, 2007
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitusPriscilla Hollander
Proceedings (Baylor University. Medical Center)|November 10, 2025
The role of insulin resistance and beta-cell response in the development of metabolic dysfunction-associated steatotic liver disease in lean individualsPriscilla Hollander
Postgraduate Medicine|December 7, 2017
Intensified insulin regimensPriscilla Hollander
Primary Care|October 22, 2003
Orlistat in the treatment of obesityPriscilla Hollander
Postgraduate Medicine|August 24, 2012
Controversies in prediabetes: do we have a diagnosis?Priscilla Hollander, Craig Spellman
Archives of Internal Medicine|June 27, 2007
Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetesPriscilla Hollander, Dahong Yu, Hubert S Chou
Journal of Diabetes and Its Complications|August 19, 2015
Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapyPriscilla Hollander, Danny Sugimoto, Aleksandra Vlajnic, et al.
Diabetes Care|August 6, 2008
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesJulio Rosenstock, Priscilla Hollander, Soazig Chevalier, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2009
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alonePriscilla Hollander, Jia Li, Elsie Allen, et al.
Clinical Therapeutics|December 26, 2008
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesPriscilla Hollander, John Cooper, Jesper Bregnhøj, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The American Journal of Medicine|February 14, 2007
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitusPriscilla Hollander
Proceedings (Baylor University. Medical Center)|November 10, 2025
The role of insulin resistance and beta-cell response in the development of metabolic dysfunction-associated steatotic liver disease in lean individualsPriscilla Hollander
Postgraduate Medicine|December 7, 2017
Intensified insulin regimensPriscilla Hollander
Primary Care|October 22, 2003
Orlistat in the treatment of obesityPriscilla Hollander
Postgraduate Medicine|August 24, 2012
Controversies in prediabetes: do we have a diagnosis?Priscilla Hollander, Craig Spellman
Archives of Internal Medicine|June 27, 2007
Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetesPriscilla Hollander, Dahong Yu, Hubert S Chou
Journal of Diabetes and Its Complications|August 19, 2015
Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapyPriscilla Hollander, Danny Sugimoto, Aleksandra Vlajnic, et al.
Diabetes Care|August 6, 2008
SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesJulio Rosenstock, Priscilla Hollander, Soazig Chevalier, et al.
The Journal of Clinical Endocrinology and Metabolism|October 30, 2009
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alonePriscilla Hollander, Jia Li, Elsie Allen, et al.
Clinical Therapeutics|December 26, 2008
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesPriscilla Hollander, John Cooper, Jesper Bregnhøj, et al.
Pageof 4